IRD

insider transactions

Opus Genetics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-1.8M

0 buy · 1.8M sell

Net value · 365d

-$7.7M

$0 in · $7.7M out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 1.8M sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Sell·S
May 18, 26

Foundation Fighting Blindness Retinal Degeneration Fund / Foundation Fighting Blindness, Inc.

Director

$7.4M

1.7M sh · $4.35

Own -31%
Sell·S
Apr 23, 26

Benjamin R Yerxa KEY

President

$39.1K

7.5K sh · $5.24

Own -1%
Sell·S
Apr 23, 26

Joseph K Schachle

Chief Operating Officer

$24.5K

4.7K sh · $5.22

Own -2%
Sell·S
Apr 23, 26

Rabourn Amy Zaremba

Head of Fin. Quality Assurance

$8.5K

1.6K sh · $5.20

Own -1%
Sell·S
Apr 23, 26

George Magrath KEY

Chief Executive Officer

$49.6K

9.5K sh · $5.22

Own -1%
Sell·S
Apr 23, 26

Ashwath Jayagopal

Chief Scientific & Dev. Ofc.

$39.2K

7.5K sh · $5.19

Own -1%
Grant·A
Apr 20, 26

Richard J Rodgers

Director

$0

24.4K sh

Own +8%
Grant·A
Apr 20, 26

James S J Manuso

Director

$0

24.4K sh

Own +8%
Grant·A
Apr 20, 26

Cam Gallagher

Director

$0

24.4K sh

Own +1%
Grant·A
Apr 20, 26

Susan Benton

Director

$0

24.4K sh

Own +11%
Grant·A
Apr 20, 26

Sean Ainsworth

Director

$0

24.4K sh

Own +8%
Sell·S
Mar 16, 26

Joseph K Schachle

Chief Operating Officer

$19.5K

3.7K sh · $5.25

Own -1%
Sell·S
Mar 16, 26

Rabourn Amy Zaremba

Head of Fin. Quality Assurance

$14.8K

2.8K sh · $5.25

Own -1%
Sell·S
Mar 16, 26

George Magrath KEY

Chief Executive Officer

$127.3K

24.4K sh · $5.21

Own -1%
Sell·S
Mar 16, 26

Ashwath Jayagopal

Chief Scientific & Dev. Ofc.

$19.0K

3.7K sh · $5.12

Own -1%
Grant·A
Feb 12, 26

James S J Manuso

Director

$0

156.2K sh

Own New
Other·F
Feb 12, 26

Ashwath Jayagopal

Chief Scientific & Dev. Ofc.

$18.0K

5.3K sh · $3.39

Own -1%
Grant·A
Jan 22, 26

Benjamin R Yerxa KEY

President

$0

400.0K sh

Own +125%
Grant·A
Jan 22, 26

Joseph K Schachle

Chief Operating Officer

$0

250.0K sh

Own +459%
Grant·A
Jan 22, 26

Rabourn Amy Zaremba

Head of Fin. Quality Assurance

$0

86.5K sh

Own +81%
Grant·A
Jan 22, 26

George Magrath KEY

Chief Executive Officer

$0

483.6K sh

Own +37%
Grant·A
Jan 22, 26

Ashwath Jayagopal

Chief Scientific & Dev. Ofc.

$0

400.0K sh

Own +318%
Other·F
Jan 18, 26

Rabourn Amy Zaremba

Head of Fin. Quality Assurance

$7.1K

3.4K sh · $2.10

Own -3%
Other·F
Jan 10, 26

Rabourn Amy Zaremba

Head of Fin. Quality Assurance

$7.6K

4.0K sh · $1.93

Own -3%
Grant·A
Jan 6, 26

Cam Gallagher

Director

$0

67.0K sh

Own +3%
Grant·A
Jan 1, 26

James S J Manuso

Director

—

31.2K sh

Own +12%
Grant·A
Jan 1, 26

Sean Ainsworth

Director

—

42.5K sh

Own +17%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
May 18, 2026	Foundation Fighting Blindness Retinal Degeneration Fund / Foundation Fighting Blindness, Inc.	Director	Sell S	1.7M	-31%	$4.35	$7.4M
Apr 23, 2026	Benjamin R Yerxa KEY	President	Sell S	7.5K	-1%	$5.24	$39.1K
Apr 23, 2026	Joseph K Schachle	Chief Operating Officer	Sell S	4.7K	-2%	$5.22	$24.5K
Apr 23, 2026	Rabourn Amy Zaremba	Head of Fin. Quality Assurance	Sell S	1.6K	-1%	$5.20	$8.5K
Apr 23, 2026	George Magrath KEY	Chief Executive Officer	Sell S	9.5K	-1%	$5.22	$49.6K
Apr 23, 2026	Ashwath Jayagopal	Chief Scientific & Dev. Ofc.	Sell S	7.5K	-1%	$5.19	$39.2K
Apr 20, 2026	Richard J Rodgers	Director	Grant A	24.4K	+8%	—	$0
Apr 20, 2026	James S J Manuso	Director	Grant A	24.4K	+8%	—	$0
Apr 20, 2026	Cam Gallagher	Director	Grant A	24.4K	+1%	—	$0
Apr 20, 2026	Susan Benton	Director	Grant A	24.4K	+11%	—	$0
Apr 20, 2026	Sean Ainsworth	Director	Grant A	24.4K	+8%	—	$0
Mar 16, 2026	Joseph K Schachle	Chief Operating Officer	Sell S	3.7K	-1%	$5.25	$19.5K
Mar 16, 2026	Rabourn Amy Zaremba	Head of Fin. Quality Assurance	Sell S	2.8K	-1%	$5.25	$14.8K
Mar 16, 2026	George Magrath KEY	Chief Executive Officer	Sell S	24.4K	-1%	$5.21	$127.3K
Mar 16, 2026	Ashwath Jayagopal	Chief Scientific & Dev. Ofc.	Sell S	3.7K	-1%	$5.12	$19.0K
Feb 12, 2026	James S J Manuso	Director	Grant A	156.2K	New	—	$0
Feb 12, 2026	Ashwath Jayagopal	Chief Scientific & Dev. Ofc.	Other F	5.3K	-1%	$3.39	$18.0K
Jan 22, 2026	Benjamin R Yerxa KEY	President	Grant A	400.0K	+125%	—	$0
Jan 22, 2026	Joseph K Schachle	Chief Operating Officer	Grant A	250.0K	+459%	—	$0
Jan 22, 2026	Rabourn Amy Zaremba	Head of Fin. Quality Assurance	Grant A	86.5K	+81%	—	$0
Jan 22, 2026	George Magrath KEY	Chief Executive Officer	Grant A	483.6K	+37%	—	$0
Jan 22, 2026	Ashwath Jayagopal	Chief Scientific & Dev. Ofc.	Grant A	400.0K	+318%	—	$0
Jan 18, 2026	Rabourn Amy Zaremba	Head of Fin. Quality Assurance	Other F	3.4K	-3%	$2.10	$7.1K
Jan 10, 2026	Rabourn Amy Zaremba	Head of Fin. Quality Assurance	Other F	4.0K	-3%	$1.93	$7.6K
Jan 6, 2026	Cam Gallagher	Director	Grant A	67.0K	+3%	—	$0
Jan 1, 2026	James S J Manuso	Director	Grant A	31.2K	+12%	—	—
Jan 1, 2026	Sean Ainsworth	Director	Grant A	42.5K	+17%	—	—

About IRD insider trading

This page tracks insider transactions for Opus Genetics, Inc. (IRD) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.